(L to R) Orca Bio co-founders Jeroen Bekaert, Ivan Dimov and Nate Fernhoff
December 11, 2021 09:30 AM ESTUpdated February 25, 06:39 AM
R&D

ASH: A cell ther­a­py start­up with roots in Irv Weiss­man­'s lab near­ly wipes out a chron­ic side ef­fect in ear­ly tri­als

Nicole DeFeudis

Editor

While a hematopoi­et­ic stem cell trans­plant is the best op­tion for some pa­tients with blood can­cer, the pro­ce­dure can lead to dan­ger­ous com­pli­ca­tions, such as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times